Annual Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease During Infliximab Maintenance Therapy: Balancing Efficacy with Risk of Pharmacokinetic Failure
Proactive TDM measuring with IFX TL annually may be helpful in maintaining therapeutic IFX TL ≥ 3 μg/mL in 85% of patients with IBD and clinical remission on infliximab maintenance therapy.
Authors
- Ok Soon Jeong (ORCID: https://orcid.org/0000-0002-6172-6329)
- Kyeongman Jeon (ORCID: https://orcid.org/0000-0002-4822-1772)
- Dong Kyung Chang (ORCID: https://orcid.org/0000-0001-8925-4629)
- Yujin Lim (ORCID: https://orcid.org/0000-0002-3076-8040)
- Eun Ran Kim (ORCID: https://orcid.org/0000-0002-0495-2565)
- Youngho Kim (ORCID: https://orcid.org/0000-0001-7531-802X)
- Boram Park (ORCID: https://orcid.org/0000-0001-6874-2199)
- Sung Noh Hong
Institutions
- Samsung Medical Center (KR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Digestive Diseases and Sciences
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1007/s10620-025-09032-9
- Citations
- 2
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 3.63
Funders
- Sungkyunkwan University